Feb 9, 2006 - regulatory T cell development,'' by Marc A. Gavin, Troy R. Torgerson, Evan ... high and low FOXP3 expression was not made for CD4+ cells ...
Below are four abstracts from the 4th Annual Conference on Arteriosclerosis, Thrombosis, and. Vascular Biology (2003 ... Lysophosphatidic acid (LPA) is the prototypic member of a class of receptor active .... by guest on July 2, 2018.
Nov 8, 2005 - Ward, Samuel V. Angiuoli, Jonathan Crabtree, Amanda L. Jones, A. Scott Durkin, Robert T. DeBoy, Tanja M. Davidsen,. Marirosa Mora, Maria ...
by accident, I found a paper (2) by G. V. Calder of Iowa State. University that did treat such a case. ... David W. Ball. Department of Chemistry. Cleveland State ...
been corrected in the HTML and PDF versions of this article. ... Correction to: Nature Medicine https://doi.org/10.1038/nm.4305, published online 10 April 2017.
IEE G, 1990,137, (2), pp. 88-94. Editor's corrections. COHEN, M. H., and ANDREOU, A. G.: 'MOS circuit for nonlinear. Hebbian learning', Electron. Lett., 1992, 28 ...
... Thearith Koeuth, Liu Pentao, Donna M. Muzny, Richard A. Gibbs & James R. Lupski ... Frederic Rosa, Monte Westerfield, Leonard I. Zon, Steve L. Johnson ...
hypothalamic lesions and low CSF hypocretin-1 levels. TM with longitudinally extensive (3 ⥠VS) and centrally located lesion. Intractable hiccups, nausea and.
Jul 18, 2000 - Addition of 5 M MPP to mesencephalic neuronal cultures resulted in a decrease ..... Analysis was performed on a Becton Dickinson FACS (fluores- ..... M. C. Jacob for FACS analysis, to Danielle Marais for cytogenetic analysis,.
May 28, 2002 - Eleonora Palma*, Anna M. Mileo†, Atau´ lfo Martínez-. Torres‡ ... Hans-Peter Zenner, and Marlies Knipper, which appeared in number 5, March ...
Hinds, W. C., Aerosol Technology: Properties, Behavior, and Measurement of.
Airborne Particles, Second Edition, Wiley, New York (1999). CORRECTIONS TO
...
rect list appears above; the corrected list of affiliations follows. ... Programs, UCSF Cancer Center, University of California at San Francisco, Box 0808, ... from the Human Genetics Program at the Albert Einstein College of Medicine (to R.K.).
Primary and predicted secondary structure of the Actinomadura R39 extraceliular DD-peptidase, a penicillin-binding protein (PBP) related to the Escherichia coli ...
degrees as their terminal degree. (two chairs, four editors, and one professional society president) and one has a nurse practitioner degree. (professional society ...
Sep 8, 2009 - George Naumov for supplying the Tsp-1 / mice. We thank Arul ... Sylvester SR, Morales C, Oko R, Griswold MD (1989) Sulfated glycoprotein-1.
John H. Lewko. Director. Centre for Research in Human. Development. Laurentian University. Sudbury, Ont. Chair. Research Advisory Committee. SMARTRISK.
enterohemorrhagic Escherichia coli inhibits PI3K/NF-κB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells. J. Immunol.
Feb 15, 2005 - O. Carruba, Salvador Moncada, and Emilio Clementi, which appeared in issue ... Jeffery C. Young, Gordon Armstrong, Nathan Foster, Naomi ...... Abrahams, S., Tanner, G. J., Larkin, P. J. & Ashton, A. R. (2002) Plant Physiol.
Corrections for Digital Systems Design Using VHDL. Look on the back of the title
page in your copy of the textbook. If there is a line that reads: 00 01 -- 10 9 8 7 6 ...
San Francisco Bay. Area. 11.1%. By County of ... San Luis Obispo. 757. 0.5. Humboldt. 613. 0.4 ...... CA 96127 ⢠(530)
This process of 'growing up' can lead to new adult roles ... development of a new pro-social, Aboriginal identity. ....
The PCL: SV total, Factor 1, and Factor 2 scores correlated .50, .37, and .53,
respectively .... Distribution of STAXI-2 Scores for the False Positive Interview.
Group.
tion that intensive supervision programs are making to corrections' mission. .... Special masters, monitors, or mediators have been appointed to deal with the ..... The Community Control Program in Florida, for example, utilizes house arrest, ..... E
Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer ( ...
Corrections
TLO_DEC_Correction3 S1470-2045(15)00497-0 Linked to DOI:10.1016/S14702045(15)00216-8
Correction to Lancet Oncol 2015; 16: 1499 Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1493–1505—In this Article, the colours of the curves in both panels of figure 3 were inverted; the correct version is below. These corrections have been made to the online version as of Nov 30, 2015.
A Progression-free survival from maintenance (%)
100
n Bevacizumab 228 Bevacizumab plus erlotinib 224
75
4·9 (4·1-5·7) 5·4 (4·3-6·2)
25
0
Number at risk Bevacizumab 228 Bevacizumab 224 plus erlotinib
6
12
18
24
30
79 83
16 30
8 12
2 5
0 2
Events (n)
Median (95% CI)
177 154
22·1 (19·6–26·7) 24·9 (21·4–28·9)
B
n
100 Overall survival from maintenance (%)
Median (95% CI)
187 169
Stratified hazard ratio 0·81 (0·66–1·01) p=0·059 (log-rank) Unstratified hazard ratio 0·78 (0·68–0·96) p=0·019 (log-rank) Restricted mean survival (maximum follow-up 24 weeks) p=0·023
50
0
Bevacizumab 228 Bevacizumab plus erlotinib 224
Stratified hazard ratio 0·79 (0·63–0·99) p=0·036 (log-rank) Unstratified hazard ratio 0·79 (0·64–0·98) p=0·035 (log-rank) Restricted mean survival (maximum follow-up 24 weeks) p=0·024
75
50
25
0
0
Number at risk Bevacizumab 228 Bevacizumab 224 plus erlotinib
